Cytokinetics misses by $0.42, misses on revs; guides FY24 revs below consensus (80.99 +1.99)
- Reports Q4 (Dec) loss of $1.38 per share, $0.42 worse than the FactSet Consensus of ($0.96); revenues fell 10.5% year/year to $1.7 mln vs the $7.62 mln FactSet Consensus.
- Co issues downside guidance for FY24, sees FY24 revs of $3-$5 mln vs. $25.90 mln FactSet Consensus. Operating expenses will be in the range of $420 to 450 million, and net cash utilization will be approximately $390 to $420 million.